Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Islet Sciences, a biotechnology company, has signed a license agreement with the University of California (UCLA) to commercialize small molecules for islet expansion.
Subscribe to our email newsletter
Islet has licensed technology from the University of California to commercialize an invention for expanding pancreatic islets.
Islet Sciences chief scientific officer Dr. Jonathan Lakey said in the course of research conducted at the University of California, Los Angeles, Dr. Anil Bhushan and Dr. Sangeeta Dhawan have developed a technology entitled small molecules for islet expansion.
"We are pleased to work with UCLA in bringing this promising technology to the next level as we look to commercialize it to benefit the growing worldwide diabetic community," Dr. Lakey added.
Islet Sciences is a development-stage biotechnology company with patented technologies focused on transplantation therapy for people with insulin-dependent diabetes.
The company’s transplantation technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells.